
|Videos|July 31, 2020
AsclepiX lead candidate holds potential for wet AMD, DME, RVO (ASRS 2020)
Author(s)Alex Delaney-Gesing , Sheryl Stevenson
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Q&A: Nadia Waheed on the role of OCT in the future of ophthalmology
2
Positive pediatric data emerge from the OPGx-LCA5 phase 1/2 trial of Leber congenital amaurosis type 5
3
Researchers assess atropine and cyclopentolate for detecting premyopia in young children
4
Q&A: Patricio Schlottmann discusses results of AVONELLE-X faricimab extension trial
5